Blockchain Registration Transaction Record

Kairos Pharma to Present Cancer Drug Resistance Strategy at Boston Conference

Kairos Pharma to present at Discovery on Target conference, highlighting strategies to overcome cancer drug resistance and advance KROS-101 and ENV-105.

Kairos Pharma’s participation in the Discovery on Target conference highlights its innovative approach to overcoming cancer drug resistance, a major challenge in oncology that limits the long-term effectiveness of many treatments. By targeting mechanisms like CD105 and GITR, Kairos aims to restore the efficacy of standard therapies and enhance anti-tumor immune responses. If successful, these strategies could significantly improve outcomes for patients with solid tumors and other cancers, addressing a critical unmet need. For investors, the presentation may provide visibility into the company’s pipeline and potential, especially as it advances its lead candidate ENV-105. The event also underscores the role of platforms like NetworkNewsWire and IBN in disseminating important developments to the investment community.